Co announces positive results from preclinical studies using a multidrug treatment regimen including ANX-510 (CoFactor) at the American Association for Cancer Research Annual Meeting. Treatment with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback